Context Therapeutics Inc.
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
CNTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2001 MARKET STREET, 19103 PHILADELPHIA
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for solid tumors. The company focuses on building an innovative portfolio of next-generation T cell engaging (TCE) bispecific antibody therapeutics, which are designed to redirect the patient's immune system to fight cancer. Its clinical-stage pipeline includes product candidates CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE; CT-95, a Mesothelin (MSLN) x CD3 TCE; and CT-202, a Nectin-4 x CD3 TCE.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Context Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Context Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Context Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
